NCT01881048 2026-01-29
Window of Opportunity Study Targeting the Inflammatory Milieu
University of Colorado, Denver
Phase EARLY_PHASE1 Completed
Clinical Trials
101 trialsNCT02885974 2025-07-28
BLAST
Baylor College of Medicine
Phase 1 Completed
NCT02030964 2025-02-17
DFMO
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT03084536 2024-12-24
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
Washington University School of Medicine
Phase 2 Completed
NCT02641314 2024-05-10
METRO-NB2012
University of Cologne
Phase 2 Completed
NCT03728179 2024-02-20
RACIN
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT03599453 2023-07-18
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Roswell Park Cancer Institute
Phase EARLY_PHASE1 Completed
NCT00538031 2023-04-21
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00503035 2023-02-13
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT02484664 2022-01-20
COLA
Brigham and Women's Hospital
Phase 2 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02770378 2021-10-05
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
University of Ulm
Phase 1/2 Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00020878 2020-08-03
Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00062179 2020-08-03
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02151448 2020-07-20
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
University of Pittsburgh
Phase 1/2 Completed
NCT02429427 2020-06-23
REACT
Imperial College London
Phase 3 Completed
NCT02280694 2020-02-12
LDMchemoCRC
HaEmek Medical Center, Israel
Phase 2 Completed
NCT00037817 2019-09-30
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02961998 2019-09-10
Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail
Sun Yat-sen University
Phase 4 Completed
NCT03059238 2019-08-13
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
Sun Yat-sen University
Phase 3 Completed
NCT00022399 2019-02-08
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00068432 2018-10-31
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01220973 2018-06-08
Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT00290680 2018-04-10
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
Medical University of South Carolina
Phase 1 Completed
NCT00052611 2018-03-29
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01695226 2018-01-09
Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer
Maastricht University Medical Center
Phase 2 Completed
NCT00137852 2017-09-20
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01425476 2017-08-09
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
Hartford Hospital
Phase 1/2 Completed
NCT01769625 2017-08-09
Changes in Biomarkers Using Prostaglandin Inhibitors
Hartford Hospital
Phase 1/2 Completed
NCT00047281 2017-07-11
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00047294 2017-07-11
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00081848 2017-07-02
Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00582660 2017-06-15
UAB0040
University of Alabama at Birmingham
Phase 2 Completed
NCT00970502 2017-04-10
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT02401295 2017-02-23
ATRA, Celecoxib, and Itraconazole as Maintenance
University of Iowa
Phase 1 Completed
NCT00056082 2017-02-15
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
University of Kansas Medical Center
Phase 2 Completed
NCT00099047 2016-12-30
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00070057 2016-12-29
Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00005878 2016-10-13
Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00070486 2016-06-30
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00931203 2016-05-04
Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT00152828 2016-02-09
Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix
University Health Network, Toronto
Phase 1/2 Completed
NCT00596219 2015-12-23
Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00104767 2015-10-02
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT00201773 2015-06-30
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01021215 2015-04-02
Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers
National Cancer Institute (NCI)
Phase 1/2 Completed